Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
Status:
Completed
Trial end date:
2020-12-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, good and/or bad the combination of two
medications, everolimus and bevacizumab, has on kidney cancer. In this clinical trial we are
now testing these medications in combination. We think that both together might work better
that either drug alone. Importantly, both of these drugs together have been tested in
patients with a different type of kidney cancer and patients tolerated the combination well.